Gene therapy (GT) targeting ocular disorders, particularly utilizing adeno-associated virus (AAV) vectors, has shown significant progress, with one product already approved for market use. The success in retinal gene therapy can be attributed to factors like the extensive knowledge of retinal gene mutations, the small retinal surface requiring low vector stocks, and the eye’s immune-privileged status. However, adverse effects from AAV delivery have necessitated a deeper focus on risk mitigation strategies to ensure the safety and efficacy of GT. Understanding and mitigating immunological risks in AAV-mediated retinal GT are crucial for personalized and efficient treatment.
In clinical trials, immune responses to rAAV vectors have emerged as a major concern, potentially limiting their efficacy and safety. Recent attention has been directed towards innate immune responses induced by AAV, leading to inflammation and questioning the safety profile of these vectors. Ocular therapies have been at the forefront of GT advancements, benefiting from the immunomodulatory environment of the eye that helps prevent robust immune reactions that could hinder gene expression. However, instances of neuroinflammation in retinal GT trials have highlighted the need for vigilant monitoring and transparent reporting of immune responses.
The retinal immunological environment is equipped with various mechanisms that confer immune tolerance and privilege, such as the blood-retina barrier and immunosuppressive factors expressed by ocular antigen-presenting cells. Despite these protective mechanisms, inflammation can still be triggered under certain conditions, including surgical trauma, patient comorbidities, or disease pathophysiology. Microglial cells, the primary immune cells in the retina, play a crucial role in orchestrating innate immune responses and can influence the outcomes of gene therapy interventions.
Inflammatory responses in retinal gene therapy trials are influenced by a combination of factors, including the type of vector sequences used, the route of administration, and the immune status of the patient. The presence of viral and bacterial sequences in gene therapy vectors can trigger immune reactions, especially through pathways like the TLR9/MyD88 pathway, leading to pro-inflammatory cytokine release. Understanding the interplay between vector components, immune sensors, and cellular responses is essential for designing safer and more effective gene therapy strategies for retinal disorders.
To mitigate immunogenicity risks in retinal gene therapy, strategies like using less immunogenic vectors, optimizing vector sequences to avoid immune activation, and considering patient-specific factors that may influence immune responses are crucial. Engineered AAV capsids that evade preexisting immunity and novel vector selection methods offer promising avenues for enhancing the safety and efficacy of retinal gene therapy. By comprehensively assessing and addressing immunological risks associated with AAV-mediated gene transfer, personalized retinal gene therapy can be optimized to deliver safe and efficient treatment outcomes.
Tags: gene therapy, downstream, clinical trials, regulatory, viral vectors, transduction
Read more on pmc.ncbi.nlm.nih.gov